| INTRODUCTION
Psoriasis is an inflammatory skin disease that is often associated with impairment of other body systems, including the eye and ear . In psoriasis, overexpression of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α activates the innate immune response (i.e., Th17 and Th1 cells), which leads to chronic inflammation (Dattilo et al., 2018; Guarneri et al., 2018) .
Familial Mediterranean fever (FMF) is an autoinflammatory condition caused by mutations in the MEFV gene, which lead to increased IL-1β production and excess inflammation (Ozen & Bilginer, 2014) .
Although there are some case reports in literature, association of psoriasis with FMF has not been really documented in a cohort (Barut, Guler, Sezen, & Kasapcopur, 2016) . However, the prevalence of psoriasis is high in patients with FMF (Erden et al., 2018; Yildiz et al., 2019) .
Pathogenesis-oriented targeted therapies are clearly more effective than conventional systemic antipsoriatic drugs. They may also influence the course of comorbidities sharing common inflammatory pathways. Thus, evaluation of co-existing diseases in managing of psoriatic patients remains crucial.
| CASE PRESENTATION
Here, we report the case of a 55-year-old Caucasian man, who pres- 
| DISCUSSION
Topical corticosteroids are typically recommended as first-line therapy for mild to moderate psoriasis (Girolomoni et al., 2012) , while patients with moderate or severe psoriasis may require systemic therapy in combination with topical drugs (Di Lernia et al., 2018) . Biological drugs can be used to treat patients with moderate to severe psoriasis (Ceccarelli et al., 2019) including those with other immune-mediated disorders (Guarneri, Russo, Mazzeo, & Cannavo, 2014) . Although biological drugs are generally well tolerated, cases of adverse skin reactions have been reported with some drugs, including adalimumab (Guarneri, Cannavo, Lentini, & Polimeni, 2011) and ustekinumab (Guarneri et al., 2016) . Due to the potential for an increased risk of infections, and given the high prevalence of tuberculosis among patients with psoriasis, it is also important to screen for tuberculosis prior to starting biological therapy (Amerio et al., 2013) . Secukinumab is a monoclonal antibody against F I G U R E 1 Erythematosquamous plaques with mild infiltration at presentation, with a Psoriasis Area Severity Index score of 14.6 with 25% body-surface area involvement F I G U R E 2 The patient's skin condition after approximately 12 months of secukinumab treatment (Psoriasis Area Severity Index score 0) IL-17A, and is indicated for the treatment of moderate to severe plaque psoriasis in patients who require systemic treatment.
IL-17 is not only a pivotal cytokine in regulating the innate immune response, but is also crucial in autoinflammation, recruiting neutrophils, activating them and stimulating their production of IL-8.
In fact, IL-8 is the main chemoattractor of neutrophils and acts synergistically with TNF-alpha in maintaining the proinflammatory profile (Marzano, Borghi, Meroni, & Cugno, 2016) .
The snapshot of cytokine profile in FMF suggests the scenario of T cell differentiation into more diverse T cell subpopulations than it was recognized before, in particular into the Th17 and Treg lineages. Similarly, Th17 and IL-17 pathways might have a part in the development and activity of Behçet's disease lesions (Leccese & Alpsoy, 2019) .
Accordingly, our case presentation and consequent treatment option seem to support a theoretically "tailored" role for secukinumab in these patients, as highly effective in managing moderate to severe plaque-type psoriasis, together with potential activity (and, in absence of active diseases, a reasonable better safety profile than other biological drugs) on other autoimmune/autoinflammatory condition as FMF and Behçet's disease.
For these reasons, we felt confident to use this drug without further attempts using conventional systemic treatments.
To our knowledge, there are no published reports on biological drugs used in psoriatic patients also affected by FMF.
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